Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Ascites Volume (mL)
研究概览
简要总结
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.
详细描述
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.
We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 80 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with CTPV.
排除标准
- •Patients with known severe dysfunction of heart, lung, brain, kidney and other vital organs.
研究组 & 干预措施
CTPV treated with Montelukast
Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
干预措施: Montelukast (Drug)
结局指标
主要结局
Ascites Volume (mL)
时间窗: 6 month
Ascites measured by CT scanning or ultrasound (If the patients had the history of ascites before)
Hydrothorax Volume (mL)
时间窗: 6 month
Hydrothorax measured by CT scanning or ultrasound (If the patients had the history of hydrothorax before)
次要结局
未报告次要终点
研究者
Zaibo Jiang
Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University